Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. In some patients, 20 mg orally once daily may be sufficient.
* **Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as clinically indicated. Doses exceeding 40 mg twice daily should be administered cautiously. Maximum recommended dose is 240 mg per day.
## Pediatric Dosing
* **Erosive esophagitis (ages 5 to 16 years):** 20 mg to 40 mg orally once daily.
* **GERD symptoms (ages 5 to 16 years):** 20 mg orally once daily.
* **Note:** Pediatric dosing for intravenous administration or for younger ages is less established and often guided by specific institutional protocols or expert consultation.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment. However, caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of bone fractures, Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19, which may affect the metabolism of drugs like clopidogrel, though clinical significance is debated.
## Monitoring
* Monitor for signs and symptoms of fracture, Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia, especially with long-term use.
* In patients with Zollinger-Ellison syndrome, monitor gastric pH and acid output.
## Clinical Pearls
* Administer orally 30-60 minutes before a meal.
* For intravenous administration, reconstitute and dilute according to manufacturer instructions.
* Long-term use should be at the lowest effective dose and for the shortest duration necessary to treat the condition.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete details and to confirm appropriateness for individual patient care.*
